|
|
| Product Name: | E1R | | Synonyms: | E1R;1-Pyrrolidineacetamide, 2-methyl-5-oxo-3-phenyl-, (2S,3R)-;E1R,E-1R | | CAS: | 1301211-78-8 | | MF: | C13H16N2O2 | | MW: | 232.28 | | EINECS: | | | Product Categories: | | | Mol File: | 1301211-78-8.mol |  |
| Boiling point | 480.0±45.0 °C(Predicted) | | density | 1.168±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 60 mg/mL (258.31 mM) | | pka | 15.67±0.40(Predicted) | | form | Solid | | color | Light yellow to yellow |
| Biological Activity | E1R is a positive allosteric modulator of the sigma-1 receptor (Sig1R PAM) with cognitive enhancing effects. | | in vitro | The only target for E1R (inhibition or enhancement of radioligand binding exceeding 20%) is the sigma receptor. 10 μM E1R does not displace the radioligand, but instead increases the specific binding of a non-selective radioligand ([ 3 H]1,3-di(2-tolyl)guanidine) for the sigma receptor by 38% in Jurkat cells. | | in vivo | E1R demonstrates efficacy against scopolamine-induced cholinergic dysfunction in mice. Treatment with E1R (0.1-10 mg/kg; administered ip 60 min before the training session) significantly improves cognitive function in a dose-related manner in mice . | Animal Model: | Male ICR and Balb/c mice weighed 23-25 g | | Dosage: | 0.1, 1 and 10 mg/kg | | Administration: | Administered ip 60 min before the training session | | Result: | Treatment at doses of 1 and 10 mg/kg increased retention latency by 194 and 211%, respectively, compared with the control group. | |
| | E1R Preparation Products And Raw materials |
|